RhumbLine Advisers’s GeneDx Holdings WGS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.73M Buy
25,183
+1,663
+7% +$94.5K ﹤0.01% 2015
2026
Q1
$1.51M Sell
23,520
-133
-0.6% -$12.1K ﹤0.01% 2006
2025
Q4
$3.08M Sell
23,653
-3,925
-14% -$539K ﹤0.01% 1644
2025
Q3
$2.97M Sell
27,578
-32
-0.1% -$3.49K ﹤0.01% 1696
2025
Q2
$2.55M Buy
27,610
+8,258
+43% +$648K ﹤0.01% 1757
2025
Q1
$1.71M Sell
19,352
-398
-2% -$34.5K ﹤0.01% 1893
2024
Q4
$1.52M Buy
19,750
+1,021
+5% +$71.3K ﹤0.01% 2030
2024
Q3
$795K Buy
18,729
+369
+2% +$12.5K ﹤0.01% 2392
2024
Q2
$480K Buy
18,360
+18,136
+8,096% +$344K ﹤0.01% 2710
2024
Q1
$2.04K Hold
224
﹤0.01% 4088
2023
Q4
$616 Hold
224
﹤0.01% 4191
2023
Q3
$815 Sell
224
-419
-65% -$2.3K ﹤0.01% 4200
2023
Q2
$3.83K Sell
643
-10,399
-94% -$82.3K ﹤0.01% 4127
2023
Q1
$133K Buy
11,042
+3,822
+53% +$51K ﹤0.01% 2821
2022
Q4
$63K Buy
7,220
+15
+0.2% +$331 ﹤0.01% 2939
2022
Q3
$209K Buy
7,205
+406
+6% +$18.6K ﹤0.01% 2879
2022
Q2
$283K Buy
+6,799
New +$461K ﹤0.01% 2788

Other funds holding WGS

RhumbLine Advisers's WGS Position: Q2 2026 in Review

RhumbLine Advisers increased its GeneDx Holdings (WGS) stake by 7.1% in Q2 2026, buying an estimated $94.5K and bringing the position to 25,183 shares worth $1.73M. The position accounts for ﹤0.01% of the portfolio, ranked #2015.

RhumbLine Advisers first reported a position in WGS in Q2 2022 and has held it in 17 quarters since. The position peaked at $3.08M in Q4 2025. 223 funds tracked by Wall St. Rank hold WGS as of Q2 2026.

  • RhumbLine Advisers held 25,183 shares of GeneDx Holdings worth $1.73M as of Q2 2026.
  • RhumbLine Advisers bought 1,663 GeneDx Holdings shares in Q2 2026, an estimated $94.5K.
  • GeneDx Holdings made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2015 holding.
  • RhumbLine Advisers first reported a position in GeneDx Holdings in Q2 2022 and has held it in 17 quarters since.
  • RhumbLine Advisers's GeneDx Holdings position peaked at $3.08M in Q4 2025.
  • 223 funds tracked by Wall St. Rank held GeneDx Holdings as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.